The observation that VEGFR2 inhibition improved T cell exhaustion even after combined immunotherapy, including VEGF-A inhibition as primary therapy in HCC, is particularly noteworthy for future therapeutic applications. Here, VEGFA is linked to hepatocellular carcinoma.